Is CASTLE BIOSCIENCES INC (CSTL) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 4.6% / 30% | 37.1% / 30% | 5.4% / 30% | 3.42% / 5% | ✗ NOT HALAL |
| DJIM | 4.6% / 33% | 37.1% / 33% | 5.4% / 33% | 3.42% / 5% | ✗ NOT HALAL |
| MSCI | 6.4% / 33% | 51.8% / 33% | 7.5% / 33% | 3.42% / 5% | ✗ NOT HALAL |
| S&P | 4.6% / 33% | 37.1% / 33% | 5.4% / 33% | 3.42% / 5% | ✗ NOT HALAL |
| FTSE | 6.4% / 33% | 51.8% / 33% | 7.5% / 50% | 3.42% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 79.4% | |
| Operating Margin | -4.4% | |
| Net Margin | -7.0% | |
| Return on Equity (ROE) | -5.2% | |
| Return on Assets (ROA) | -2.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $64M |
| Free Cash Flow | $28M |
| Total Debt | $37M |
| Debt-to-Equity | 7.9 |
| Current Ratio | 5.3 |
| Total Assets | $579M |
Price & Trading
| Last Close | $24.70 |
| 50-Day MA | $31.85 |
| 200-Day MA | $27.81 |
| Avg Volume | 401K |
| Beta | 1.1 |
|
52-Week Range
$14.59
| |
About CASTLE BIOSCIENCES INC (CSTL)
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is CASTLE BIOSCIENCES INC (CSTL) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), CASTLE BIOSCIENCES INC is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is CASTLE BIOSCIENCES INC's debt ratio?
CASTLE BIOSCIENCES INC's debt ratio is 4.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 6.4%.
What are CASTLE BIOSCIENCES INC's key financial metrics?
CASTLE BIOSCIENCES INC has a market capitalization of $700M, and revenue of $344M. The company maintains a gross margin of 79.4% and a net margin of -7.0%. Return on equity stands at -5.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.